已收盘 12-24 16:00:00 美东时间
+0.150
+1.03%
今日重点评级关注:富国银行:维持Annexon"超配"评级,目标价从14美元升至27美元;瑞穗:上调Relmada Therapeutics评级至"跑赢大市",目标价从1美元升至10美元
11-20 10:28
RBC Capital analyst Kenneth S. Lee maintains Kayne Anderson BDC (NYSE:KBDC) with a Outperform and lowers the price target from $17 to $16.
11-20 00:00
今日重点评级关注:HC Wainwright & Co.:维持PDS Biotechnology"买入"评级,目标价从13美元升至15美元;HC Wainwright & Co.:维持PepGen Inc."买入"评级,目标价从18美元升至20美元
11-14 10:43
今日重点评级关注:HC Wainwright & Co.:维持Artiva Biotherapeutics"买入"评级,目标价从12美元升至15美元;Canaccord Genuity:维持Viking Therapeutics"买入"评级,目标价从106美元升至107美元
11-13 09:58
Wells Fargo analyst Finian O'Shea maintains Kayne Anderson BDC (NYSE:KBDC) with a Overweight and lowers the price target from $16 to $15.
11-12 23:13
Kayne Anderson BDC, Inc. (NYSE:KBDC) ("KBDC" or the "Company"), a business development company externally managed by its investment adviser, KA Credit Advisors, LLC, an affiliate of Kayne Anderson Capital Advisors, LP
11-11 05:31
Kayne Anderson BDC (NYSE:KBDC) reported quarterly earnings of $0.43 per share which beat the analyst consensus estimate of $0.40 by 8.86 percent. This is a 17.31 percent decrease over earnings of $0.52 per share from the
11-11 05:21
Companies Reporting Before The Bell • CBAK Energy Tech (NASDAQ:CBAT) is likely ...
11-10 19:12
今日重点评级关注:摩根士丹利:上调Alvotech评级至"超配",目标价14美元;蒙特利尔银行:维持PG&E"跑赢大市"评级,目标价从23美元升至25美元
10-15 18:20
UBS analyst Doug Harter maintains Kayne Anderson BDC (NYSE:KBDC) with a Neutral and lowers the price target from $16.5 to $15.
10-15 00:32